NEW YORK (360Dx) — Digital pathology firm PathAI announced today that it has closed a $60 million Series B financing round.
The round was led by new investor General Atlantic with participation from existing investors including General Catalyst. In conjunction with the round, General Atlantic Managing Director Michelle Dipp will join PathAI's board.
Boston-based PathAI said it will use the funding to continue refining its core pathology research platform — which uses artificial intelligence to assist pathologists in making accurate diagnoses from patient tissue samples — as well as support its research and development activities and existing partnerships.
In 2017, PathAI began working with Royal Philips to develop computational pathology technologies, including applications to automatically detect and quantify cancerous lesions in breast cancer tissue. Other partners include Bristol-Myers Squibb and Novartis.